Andy Chen
Stock Analyst at Wolfe Research
(4.12)
# 515
Out of 4,998 analysts
41
Total ratings
59.26%
Success rate
13.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETNB 89bio | Downgrades: Peer Perform | n/a | $14.70 | - | 2 | Sep 19, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $456.00 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $29.06 | - | 2 | Aug 4, 2025 | |
| VRNA Verona Pharma | Initiates: Outperform | $170 | $106.71 | +59.31% | 1 | Jul 1, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $51.94 | -5.66% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $19.27 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $43.57 | +26.23% | 1 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $7.17 | +750.77% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $17.27 | +21.60% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $30.62 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $41.65 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $19.23 | +4.00% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $22.20 | -14.41% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $16.12 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $737.56 | -5.50% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $84.81 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $25.87 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $56.60 | +14.84% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $47.48 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $458.66 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.58 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $25.79 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $65.42 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $64.81 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $15.13 | +12.36% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $391.64 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $144.01 | -70.84% | 1 | Feb 15, 2024 |
89bio
Sep 19, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $14.70
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $456.00
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $29.06
Upside: -
Verona Pharma
Jul 1, 2025
Initiates: Outperform
Price Target: $170
Current: $106.71
Upside: +59.31%
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $51.94
Upside: -5.66%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $19.27
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $43.57
Upside: +26.23%
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $7.17
Upside: +750.77%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $17.27
Upside: +21.60%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $30.62
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $41.65
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $19.23
Upside: +4.00%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $22.20
Upside: -14.41%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $16.12
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $737.56
Upside: -5.50%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $84.81
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $25.87
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $56.60
Upside: +14.84%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $47.48
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $458.66
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $21.58
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $25.79
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $65.42
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $64.81
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $15.13
Upside: +12.36%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $391.64
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $144.01
Upside: -70.84%